



Press Release  
Friday, May 15, 2009

Strides Arcolab Limited,  
Strides House,  
Bannerghatta Road,  
Bangalore – 560076, India

BSE: 532531  
NSE: STAR

---

## Strides Arcolab announces 2 ANDA approvals For Adenosine Injection USP and Meloxicam Tablets USP

Total approvals in Steriles space at 16 and Orals space at 12

---

Strides Arcolab Limited (Strides) today announced receipt of 2 ANDA approvals for:

1. **Adenosine Injection USP**, 3 mg / mL, packaged in 6 mg / 2 mL Single dose Vials
2. **Meloxicam Tablets USP**, 7.5 mg and 15 mg.

The approval of Adenosine Injection takes total sterile products approvals to 16 and Meloxicam Tablets takes total Oral products approvals to 12.

V.S. Iyer, CEO – India Operations stated: “We are delighted with the continued flow of speedy regulatory approvals, which demonstrates our strength in Manufacturing and R&D.

**About Adenosine Injection** - *Adenosine Injection is a cardiovascular agent and is the generic equivalent of Adenocard<sup>®</sup> of Astellas Pharma Inc.*

**About Meloxicam Tablets** - *Meloxicam tablets is a non-steroidal anti-inflammatory agent and is the generic equivalent of Mobic<sup>®</sup> of Boehringer Ingelheim Pharmaceuticals, Inc.*

### **About Strides Arcolab Limited**

Strides, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a Bangalore, India head quartered global pharmaceutical company. Strides manufactures pharmaceutical formulations in various dosage forms including sterile injectables with dedicated facilities for Penicillin and Penems, Cephalosporins, Oncolytics and lyophilized injectable products. The company also manufactures pharmaceutical formulations in oral dosage forms, including capsules & tablets and Softgel capsules. Strides operates in and has significant presence in Australasia, Africa and India and through a series of strategies is expanding its North American and European growth. The company has series of joint ventures and front-ended operations in major markets and is a majority stakeholder of Ascent Pharmahealth Limited (APH), an ASX listed company. The company also collaborates closely with Global Drug Agencies and US PEPFAR and the UNICEF to supply a range of affordable generic pharmaceutical products used in the treatment of HIV, TB and Malaria.

Strides has manufacturing facilities in Bangalore, India and overseas facilities in Milan, Warsaw, Singapore and Lagos. The Indian manufacturing facilities are approved by all major regulatory bodies. Strides employs approximately 2,500 people across the globe. Strides also has a marketing presence in over 50 countries.

Additional information is available at the company's website at [www.stridesarco.com](http://www.stridesarco.com)

<p><b>For further information, please contact:</b></p> <p><i>For products information:</i></p> <p>Mr. V.S.Iyer, CEO – India Operations Ph: +91 80 6658 0111 Email: <a href="mailto:venkat.iyer@stridesarco.com">venkat.iyer@stridesarco.com</a></p> <p><i>For Company information:</i></p> <p>Mr. Kannan N, Company Secretary Ph: +91 80 6658 0751 Email: <a href="mailto:kannan.n@stridesarco.com">kannan.n@stridesarco.com</a></p>	<p>Mr. Mahesh Nair Corporate Voice/ Weber Shandwick Mobile : +91 98803 76648 Email: <a href="mailto:maheshn@corvoshandwick.co.in">maheshn@corvoshandwick.co.in</a></p> <p>Ms. Kasturi Wasmatkar Corporate Voice/ Weber Shandwick Mobile: +91 99167 28393 Email: <a href="mailto:kasturi@corvoshandwick.co.in">kasturi@corvoshandwick.co.in</a></p>
--	--